MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bjh.17673

Медицинская библиотека · British journal of haematology · 2021

Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.

Topp Max S, van Meerten Tom, Houot Roch, Minnema Monique C, Bouabdallah Krimo, Lugtenburg Pieternella J, Thieblemont Catherine, Wermke Martin, Song Kevin W, Avivi Irit, Kuruvilla John, Dührsen Ulrich, Zheng Yan, Vardhanabhuti Saran, Dong Jinghui, Bot Adrian, Rossi John M, Plaks Vicki, Sherman Marika, Kim Jenny J, Kerber Anne, Kersten Marie José

Клиническое исследование I фазыКлиническое исследование II фазыСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed or refractory large B-cell lymphoma (R/R LBCL). To reduce axi-cel-related toxicity, several exploratory safety management cohorts were added to ZUMA-1 (NCT02348216), the pivotal phase 1/2 study of axi-cel in refractory LBCL. Cohort 4 evaluated the rates and severity of cytokine release syndrome (CRS) and neurologic events (NEs) with earlier corticosteroid and tocilizumab use. Primary endpoints were incidence and severity of CRS and NEs. Patients received 2 × 106 anti-CD19 CAR T cells/kg after conditioning chemotherapy. Forty-one patients received axi-cel. Incidences of any-grade CRS and NEs were 93% and 61%, respectively (grade ≥ 3, 2% and 17%). There was no grade 4 or 5 CRS or NE. Despite earlier dosing, the cumulative cortisone-equivalent corticosteroid dose in patients requiring corticosteroid therapy was lower than that reported in the pivotal ZUMA-1 cohorts. With a median follow-up of 14·8 months, objective and complete response rates were 73% and 51%, respectively, and 51% of treated patients were in ongoing response. Earlier and measured use of corticosteroids and/or tocilizumab has the potential to reduce the incidence of grade ≥ 3 CRS and NEs in patients with R/R LBCL receiving axi-cel.

Для цитирования: Topp Max S, van Meerten Tom, Houot Roch, Minnema Monique C, Bouabdallah Krimo, Lugtenburg Pieternella J, Thieblemont Catherine, Wermke Martin, Song Kevin W, Avivi Irit, Kuruvilla John, Dührsen Ulrich, Zheng Yan, Vardhanabhuti Saran, Dong Jinghui, Bot Adrian, Rossi John M, Plaks Vicki, Sherman Marika, Kim Jenny J, Kerber Anne, Kersten Marie José. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.. British journal of haematology. 2021. DOI: 10.1111/bjh.17673.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.